Most human observational and intervention evidence for the effects of these drugs has been derived from populations with type 2 diabetes mellitus, and there is a need for intervention studies for older people with, and at risk of, sarcopenia to further investigate the balance of benefit and risk in these target populations
Although it was hoped that, given lower manufacturing costs, the oral version would be priced lower than the injectable, currently that is not the case
Conventional therapies targeting classical risk factors, such as hypertension, diabetes mellitus, and dyslipidemia, confer partial protective effects but do not completely halt DKD progression or sufficiently mitigate its associated cardiovascular risk [6]
Researchers might monitor cell morphology, gene expression changes, or biochemical markers such as oxidative stress indicators and extracellular matrix components
The medications have surged in popularity in recent years, but not all the attention has been positive